Novel Psilocin Derivatives as Serotonergic Psychedelic Agents for Treating CNS Disorders
ACS Medicinal Chemistry Letters October 22, 2025 DOI: 10.1021/acsmedchemlett.5c00608 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Serotonin Psilocybin |
| Keywords | Central nervous system Hallucinogen Neuropharmacology |
Abstract
High Resolution Image Download MS PowerPoint Slide Provided herein are novel psilocin derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating central nervous system (CNS) disorders, and processes for preparing such compounds.
Citations in the library
Cites 4
- 5-HT2A receptors: Pharmacology and functional selectivity. Pharmacological Reviews April 23, 2025
- Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications. Brain Sciences January 25, 2025
- Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature. Brain Research 2025
- Exploring DMT: Endogenous role and therapeutic potential. Neuropharmacology May 1, 2025